Prudent Man Advisors LLC Sells 245 Shares of Merit Medical Systems, Inc. (NASDAQ:MMSI)

Prudent Man Advisors LLC lessened its holdings in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 9.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,222 shares of the medical instruments supplier’s stock after selling 245 shares during the quarter. Prudent Man Advisors LLC’s holdings in Merit Medical Systems were worth $215,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of MMSI. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Merit Medical Systems in the third quarter valued at about $325,000. Farther Finance Advisors LLC boosted its position in shares of Merit Medical Systems by 32.7% in the third quarter. Farther Finance Advisors LLC now owns 1,056 shares of the medical instruments supplier’s stock valued at $104,000 after acquiring an additional 260 shares during the period. Van ECK Associates Corp bought a new stake in Merit Medical Systems during the third quarter worth about $718,000. QRG Capital Management Inc. lifted its position in Merit Medical Systems by 16.9% during the third quarter. QRG Capital Management Inc. now owns 8,572 shares of the medical instruments supplier’s stock worth $847,000 after purchasing an additional 1,240 shares during the period. Finally, Impax Asset Management Group plc bought a new stake in Merit Medical Systems during the third quarter worth about $11,860,000. Institutional investors own 99.66% of the company’s stock.

Merit Medical Systems Stock Up 3.6 %

Shares of NASDAQ MMSI opened at $102.04 on Friday. The company has a current ratio of 5.36, a quick ratio of 3.82 and a debt-to-equity ratio of 0.57. The company has a market cap of $5.95 billion, a price-to-earnings ratio of 50.02, a PEG ratio of 2.34 and a beta of 0.87. Merit Medical Systems, Inc. has a 12 month low of $70.70 and a 12 month high of $111.45. The stock has a 50-day moving average price of $102.91 and a two-hundred day moving average price of $100.03.

Wall Street Analysts Forecast Growth

MMSI has been the subject of several recent analyst reports. StockNews.com cut shares of Merit Medical Systems from a “buy” rating to a “hold” rating in a research report on Sunday, November 3rd. Needham & Company LLC cut their price objective on shares of Merit Medical Systems from $122.00 to $116.00 and set a “buy” rating for the company in a research report on Wednesday. Piper Sandler reaffirmed an “overweight” rating and set a $116.00 price objective (up previously from $114.00) on shares of Merit Medical Systems in a research report on Wednesday, January 29th. Canaccord Genuity Group cut their price objective on shares of Merit Medical Systems from $128.00 to $127.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Wells Fargo & Company cut their price objective on shares of Merit Medical Systems from $120.00 to $117.00 and set an “overweight” rating for the company in a research report on Wednesday. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $110.78.

Merit Medical Systems Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.